Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 20 to 45, healthy male subjects(at screening)~* Body weight between 55kg - 90kg, BMI between 18.0 - 27.0~* FPG 70-125mg/dL glucose level(at screening)~* Subject who totally understand the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the progress.~Exclusion Criteria:~* Subject who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)~* Subject who had GI tract disease or(ulcer, acute or chronic pancreatitis) surgery.(appendectomy, hernioplasty are not included)~* Subject who had drug hypersensitivity reaction.(Aspirin, antibiotics)~* Subject who already participated in other trials in 2months~* Subject who had whole blood donation in 2months, or component blood donation in 1months or transfusion in 1months currently.~* Smokers.(but, if the subject did'nt smoke in 3months, can participate the trial)

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- LC15-0444 (Type: EXPERIMENTAL): LC15-0444 50mg qd
- Metformin (Type: EXPERIMENTAL): Metformin 1000mg bid
- LC15-0444+Metformin (Type: EXPERIMENTAL): LC15-0444 50mg qd +Metformin 1000mg bid

Based on this trial design, predict the completion outcome and termination type (if applicable).